Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę "Merkelbach, Matthias" wg kryterium: Autor


Tytuł :
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
Autorzy :
Scheffler M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Wiesweg M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Michels S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Nogová L; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Kron A; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Herold T; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
Scheel AH; Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Germany.
Metzenmacher M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Eberhardt WE; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Reis H; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
Fassunke J; Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Germany.
Darwiche K; Department of Pulmonary Medicine, Section of Interventional Pneumology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Aigner C; Department of Thoracic Surgery and Endoscopy, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Schaufler D; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Riedel R; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Fischer R; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Koleczko S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Schildhaus HU; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
Merkelbach-Bruse S; Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Germany.
Schmid KW; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
Büttner R; Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Germany.
Wolf J; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Germany. Electronic address: .
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2022 Jun; Vol. 168, pp. 10-20. Date of Electronic Publication: 2022 Apr 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/pathology
ErbB Receptors/genetics ; Humans ; Mutation ; Prognosis ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics
Czasopismo naukowe
Tytuł :
Reply to: "Survival Analysis of TP53 Co-Mutations Should be Interpreted More Cautiously".
Autorzy :
Saleh MM; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Merkelbach-Bruse S; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Buettner R; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Jun; Vol. 17 (6), pp. e57-e59.
Typ publikacji :
Letter; Comment
MeSH Terms :
Lung Neoplasms*/genetics
Humans ; Mutation ; Survival Analysis ; Tumor Suppressor Protein p53/genetics
Opinia redakcyjna
Tytuł :
Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC.
Autorzy :
Saleh MM; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Merkelbach-Bruse S; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheel AH; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Ulmer B; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Buettner R; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Jan; Vol. 17 (1), pp. 76-88. Date of Electronic Publication: 2021 Sep 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Kelch-Like ECH-Associated Protein 1*/genetics
Lung Neoplasms*/genetics
Tumor Suppressor Protein p53*/genetics
Carcinoma, Non-Small-Cell Lung/*genetics
Humans ; Mutation ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.
Autorzy :
Schaufler D; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Ast DF; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; Mildred Scheel School of Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Tumbrink HL; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Abedpour N; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne, Cologne, Germany.
Maas L; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Schwäbe AE; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Spille I; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Lennartz S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Fassunke J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.
Aldea M; Department of medical oncology, Thoracic Group, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris, France.
Besse B; Department of medical oncology, Thoracic Group, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris, France.
Planchard D; Department of medical oncology, Thoracic Group, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris, France.
Nogova L; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Michels S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Kobe C; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Cologne, Germany.
Persigehl T; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Diagnostic and Interventional Radiology, Cologne, Germany.
Westphal T; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Koleczko S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Fischer R; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Weber JP; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Altmüller J; Cologne Center for Genomics, University of Cologne, Cologne, Germany.
Thomas RK; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.; DKFZ, German Cancer Research Center, German Cancer Consortium (DKTK), Heidelberg, Germany.
Merkelbach-Bruse S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.
Gautschi O; University of Bern and Cantonal Hospital of Lucerne, Lucerne, Switzerland.
Mezquita L; Medical Oncology Department, Hospital Clinic, Laboratory of Translational Genomics and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
Büttner R; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.
Wolf J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Peifer M; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Brägelmann J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany. .; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany. .; Mildred Scheel School of Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. .; University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne, Cologne, Germany. .
Scheffler M; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany. matthias..
Sos ML; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany. .; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany. .; University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne, Cologne, Germany. .
Pokaż więcej
Źródło :
NPJ precision oncology [NPJ Precis Oncol] 2021 Dec 17; Vol. 5 (1), pp. 102. Date of Electronic Publication: 2021 Dec 17.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Autorzy :
Kron A; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Scheffler M; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Heydt C; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Ruge L; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Schaepers C; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Eisert AK; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Merkelbach-Bruse S; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Riedel R; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Nogova L; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Fischer RN; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Michels S; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Abdulla DSY; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Koleczko S; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Fassunke J; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Schultheis AM; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Kron F; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany; FOM University of Applied Sciences, Essen, Germany.
Ueckeroth F; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Wessling G; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Sueptitz J; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Beckers F; Network Genomic Medicine, Cologne, Germany; Department of Thoracic Surgery, St. Vinzenz-Hospital Cologne, Cologne, Germany.
Braess J; Network Genomic Medicine, Cologne, Germany; Department of Hematology and Oncology, Hospital Barmherzige Brueder Regensburg, Regensburg, Germany.
Panse J; Network Genomic Medicine, Cologne, Germany; Department of Internal Medicine IV, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital RWTH Aachen, Aachen, Germany.
Grohé C; Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Evangelische Lungenklinik Berlin, Berlin, Germany.
Hamm M; Network Genomic Medicine, Cologne, Germany; Department of Pneumology and Respiratory Medicine, Helios Medical Center of Hildesheim, Hildesheim, Germany.
Kabitz HJ; Network Genomic Medicine, Cologne, Germany; Department of Internal Medicine II, Clinic of Konstanz, Konstanz, Germany.
Kambartel K; Network Genomic Medicine, Cologne, Germany; Department of Thoracic Oncology and Interventional Bronchology, Hospital Bethanien Moers, Moers, Germany.
Kaminsky B; Network Genomic Medicine, Cologne, Germany; Department of Pneumonology and Allergology, Hospital Bethanien Solingen, Solingen, Germany.
Krueger S; Network Genomic Medicine, Cologne, Germany; Department of Pneumonology, Florence-Nightingale Hospital Düsseldorf, Düsseldorf, Germany.
Schulte C; Network Genomic Medicine, Cologne, Germany; Joint Private Practice for Hematology/Oncology, Dortmund, Germany.
Lorenz J; Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Hospital Luedenscheid, Luedenscheid, Germany.
Lorenzen J; Network Genomic Medicine, Cologne, Germany; Department of Pathology, Hospital Dortmund, Dortmund, Germany.
Meister W; Network Genomic Medicine, Cologne, Germany; Department of Thoracic Oncology and Interventional Bronchology, Helios Medical Center of Hildesheim, Hildesheim, Germany.
Meyer A; Network Genomic Medicine, Cologne, Germany; Department of Pulmonary Medicine, Maria Hilf Hospital GmbH, Moenchengladbach, Germany.
Kappes J; Network Genomic Medicine, Cologne, Germany; Department of Internal Medicine and Pneumology, Catholic Hospital Koblenz, Koblenz, Germany.
Reinmuth N; Network Genomic Medicine, Cologne, Germany; Department of Oncology, Asklepios Clinic Munich-Gauting, Munich-Gauting, Germany.
Schaaf B; Network Genomic Medicine, Cologne, Germany; Department of Respiratory Medicine and Infectious Diseases, Medical Center North of Dortmund, Dortmund, Germany.
Schulte W; Network Genomic Medicine, Cologne, Germany; Department of Pneumology and Allergology, GFO Clinic Bonn, Bonn, Germany.
Serke M; Network Genomic Medicine, Cologne, Germany; Department of Pneumology and Oncology, Evangelic Hospital Hamm, Hamm, Germany.
Buettner R; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Wolf J; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Apr; Vol. 16 (4), pp. 572-582. Date of Electronic Publication: 2020 Dec 09.
Typ publikacji :
Journal Article
MeSH Terms :
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Genetic Heterogeneity ; Humans ; Immunotherapy ; In Situ Hybridization, Fluorescence ; Mutation ; Proto-Oncogene Proteins c-met/genetics
Czasopismo naukowe
Tytuł :
Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
Autorzy :
Gassa A; Department of Cardiothoracic Surgery, University of Cologne, Germany; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany. Electronic address: .
Fassunke J; Institute of Pathology, University of Cologne, Germany.
Schueten S; Department of Cardiothoracic Surgery, University of Cologne, Germany; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany; School of Medicine, University of Cologne, Germany.
Kuhlmann L; Department of Cardiothoracic Surgery, University of Cologne, Germany; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany; School of Medicine, University of Cologne, Germany.
Scherer M; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany; School of Medicine, University of Cologne, Germany.
Qien J; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany.
Zhao Y; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany.
Michel M; Institute of Zoology, University of Cologne, Germany.
Loeser H; Institute of Pathology, University of Cologne, Germany.
Wolf J; Department of Internal Medicine I, University of Cologne, Germany.
Buettner R; Institute of Pathology, University of Cologne, Germany.
Doerr F; Department of Cardiothoracic Surgery, University of Cologne, Germany.
Heldwein M; Department of Cardiothoracic Surgery, University of Cologne, Germany.
Hagmeyer L; Hospital Bethanien Solingen, Institute of Pneumology, University of Cologne, Solingen, Germany.
Frank K; Department of Internal Medicine III, University of Cologne, Germany.
Merkelbach-Bruse S; Institute of Pathology, University of Cologne, Germany.
Quaas A; Institute of Pathology, University of Cologne, Germany.
Bruns C; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany.
Hekmat K; Department of Cardiothoracic Surgery, University of Cologne, Germany.
Weiss J; Department of Internal Medicine I, University of Cologne, Germany.
Wahlers T; Department of Cardiothoracic Surgery, University of Cologne, Germany.
Alakus H; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany.
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2021 Jan; Vol. 151, pp. 91-96. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Circulating Tumor DNA*/genetics
Lung Neoplasms*/diagnosis
Lung Neoplasms*/genetics
Neoplasm Recurrence, Local*/genetics
Biomarkers, Tumor/genetics ; High-Throughput Nucleotide Sequencing ; Humans ; Mutation ; Polymerase Chain Reaction ; Prospective Studies
Czasopismo naukowe
Tytuł :
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.
Autorzy :
Kirchner M; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Glade J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Lehmann U; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Merkelbach-Bruse S; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Hummel M; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Lehmann A; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Trautmann M; Institute of Pathology, University Hospital Münster, Münster, Germany.
Kumbrink J; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Jung A; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Dietmaier W; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Endris V; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Kazdal D; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Ploeger C; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Evert M; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Horst D; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Kreipe H; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Kirchner T; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Wardelmann E; Institute of Pathology, University Hospital Münster, Münster, Germany.
Büttner R; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Weichert W; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Dietel M; Institute of Pathology, Charité University Hospital, Berlin, Germany.; Quality Assurance Initiative in Pathology (QuiP), Berlin, Germany.
Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Pfarr N; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Pokaż więcej
Źródło :
Genes, chromosomes & cancer [Genes Chromosomes Cancer] 2020 Aug; Vol. 59 (8), pp. 445-453. Date of Electronic Publication: 2020 May 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*genetics
Genetic Testing/*methods
Neoplasms/*genetics
Oncogene Proteins, Fusion/*genetics
RNA-Seq/*methods
Receptor Tyrosine Kinase-like Orphan Receptors/*genetics
Genetic Testing/standards ; Humans ; In Situ Hybridization, Fluorescence/methods ; Neoplasms/diagnosis ; RNA-Seq/standards ; Sensitivity and Specificity ; Tissue Preservation/methods
Czasopismo naukowe
Tytuł :
Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment.
Autorzy :
Nogova, Lucia (AUTHOR)
Mattonet, Christian (AUTHOR)
Scheffler, Matthias (AUTHOR)
Taubert, Max (AUTHOR)
Gardizi, Masyar (AUTHOR)
Sos, Martin L. (AUTHOR)
Michels, Sebastian (AUTHOR)
Fischer, Rieke N. (AUTHOR)
Limburg, Meike (AUTHOR)
Abdulla, Diana S.Y. (AUTHOR)
Persigehl, Thorsten (AUTHOR)
Kobe, Carsten (AUTHOR)
Merkelbach‐Bruse, Sabine (AUTHOR)
Franklin, Jeremy (AUTHOR)
Backes, Heiko (AUTHOR)
Schnell, Roland (AUTHOR)
Behringer, Dirk (AUTHOR)
Kaminsky, Britta (AUTHOR)
Eichstaedt, Martina (AUTHOR)
Stelzer, Christoph (AUTHOR)
Pokaż więcej
Źródło :
Cancer Medicine. Jul2020, Vol. 9 Issue 14, p4991-5007. 17p.
Czasopismo naukowe
Tytuł :
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
Autorzy :
Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC) Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany. Electronic address: .
Endris V; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Budczies J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Merkelbach-Bruse S; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Kazdal D; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC) Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany.
Dietmaier W; Institute of Pathology, University Regensburg, Regensburg, Germany.
Pfarr N; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Siebolts U; Institute of Pathology, University Hospital Halle, Halle, Germany.
Hummel M; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Herold S; Institute of Pathology, University Hospital Dresden, Dresden, Germany.
Andreas J; Institute of Hematopathology, Hamburg, Germany.
Zoche M; Institute of Pathology, University Hospital Zurich, Zurich, Switzerland.
Tögel L; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany.
Rempel E; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Maas J; Quality in Pathology (QuIP), Berlin, Germany.
Merino D; Friends of Cancer Research (FoCR), Washington, District of Columbia.
Stewart M; Friends of Cancer Research (FoCR), Washington, District of Columbia.
Zaoui K; Department of Otorhinolaryngology, University Hospital Heidelberg, Heidelberg, Germany.
Schlesner M; Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Glimm H; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT Dresden) and University Hospital Carl Gustav Carus, Dresden, and Translational Functional Cancer Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK), Dresden, Germany.
Fröhling S; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Allen J; Friends of Cancer Research (FoCR), Washington, District of Columbia.
Horst D; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Baretton G; Institute of Pathology, University Hospital Dresden, Dresden, Germany.
Wickenhauser C; Institute of Pathology, University Hospital Halle, Halle, Germany.
Tiemann M; Institute of Hematopathology, Hamburg, Germany.
Evert M; Institute of Pathology, University Regensburg, Regensburg, Germany.
Moch H; Institute of Pathology, University Hospital Zurich, Zurich, Switzerland.
Kirchner T; Institute of Pathology, Ludwig-Maximilians University (LMU), Munich, Germany.
Büttner R; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Jung A; Institute of Pathology, Ludwig-Maximilians University (LMU), Munich, Germany.
Haller F; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany.
Weichert W; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Dietel M; Quality in Pathology (QuIP), Berlin, Germany.
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2020 Jul; Vol. 15 (7), pp. 1177-1189. Date of Electronic Publication: 2020 Feb 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Lung Neoplasms*/genetics
Biomarkers, Tumor/genetics ; Humans ; Mutation ; Reference Standards ; Whole Exome Sequencing
Czasopismo naukowe
Tytuł :
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
Autorzy :
Scheffler M; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Holzem A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Kron A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Nogova L; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Ihle MA; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
von Levetzow C; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Fassunke J; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Wömpner C; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Bitter E; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Koleczko S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Abdulla DSY; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Michels S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Fischer R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Riedel R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Weber JP; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Westphal T; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Gerigk U; GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany.
Kern J; KWM Missio Clinic, Würzburg, Germany.
Kaminsky B; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Randerath W; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Kambartel KO; Bethanien Hospital Moers, Lung Center, Moers, Germany.
Merkelbach-Bruse S; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Büttner R; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Wolf J; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2020 Jun; Vol. 144, pp. 40-48. Date of Electronic Publication: 2020 Apr 24.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Kelch-Like ECH-Associated Protein 1 ; MAP Kinase Kinase 1/genetics ; Mutation ; NF-E2-Related Factor 2 ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics
Czasopismo naukowe
Tytuł :
Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.
Autorzy :
Pfarr N; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Kirchner M; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Lehmann U; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Leichsenring J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Merkelbach-Bruse S; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Glade J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Hummel M; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Stögbauer F; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Lehmann A; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Trautmann M; Gerhard-Domagk-Institute of Pathology, and Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Kumbrink J; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Jung A; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Dietmaier W; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Endris V; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Kazdal D; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Evert M; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Horst D; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Kreipe H; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Kirchner T; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Wardelmann E; Gerhard-Domagk-Institute of Pathology, and Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Lassen U; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Büttner R; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Weichert W; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Dietel M; Quality Initiative in Pathology (QuiP), Berlin, Germany.
Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Genes, chromosomes & cancer [Genes Chromosomes Cancer] 2020 Mar; Vol. 59 (3), pp. 178-188. Date of Electronic Publication: 2019 Nov 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor*
Genetic Testing*/methods
High-Throughput Nucleotide Sequencing*/methods
High-Throughput Nucleotide Sequencing*/standards
Receptors, Nerve Growth Factor/*genetics
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Clinical Decision-Making ; Disease Management ; Female ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Infant ; Male ; Middle Aged ; Neoplasms/diagnosis ; Neoplasms/genetics ; Neoplasms/metabolism ; Receptors, Nerve Growth Factor/metabolism ; Reproducibility of Results ; Workflow ; Young Adult
Czasopismo naukowe
Tytuł :
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
Autorzy :
Riedel R; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Michels S; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Heydt C; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Siemanowski J; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Kobe C; Department for Nuclear Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Bunck A; Department for Radiology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Schäfer S; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Fischer RN; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Scheffler M; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Abdulla DSY; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Nogová L; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Koleczko S; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Merkelbach-Bruse S; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Büttner R; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Wolf J; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2019 Jul; Vol. 133, pp. 20-22. Date of Electronic Publication: 2019 May 06.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Adenocarcinoma of Lung/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Mutation/*genetics
Proto-Oncogene Proteins c-met/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adenocarcinoma of Lung/genetics ; Biomarkers, Tumor/genetics ; Carcinogenesis/genetics ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Amplification ; Humans ; Lung Neoplasms/genetics ; Middle Aged ; Proto-Oncogene Proteins c-met/antagonists & inhibitors ; Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Autorzy :
Michels S; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Massutí B; Department of Oncology, Alicante University Hospital-ISABIAL, Alicante, Spain.
Schildhaus HU; Institute of Pathology, University Hospital Goettingen, Göttingen, Germany and Targos Molecular Pathology, Kassel, Germany.
Franklin J; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
Sebastian M; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
Felip E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Grohé C; Department of Pneumology, Protestant Lung Hospital Berlin, Berlin, Germany.
Rodriguez-Abreu D; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Abdulla DSY; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Bischoff H; Thoraxonkologie, Thoraxklinik, Heidelberg, Germany.
Brandts C; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
Carcereny E; Servei d'Oncologia Mèdica, Institut Català d'Oncologia Badalona-Hospital Germans Trias i Pujol, Carretera de Canyet, Badalona, Spain.
Corral J; Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain; prior affiliation during the trial: Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Dingemans AC; Department for Oncology, Maastricht University Medical Center, Maastricht, Netherlands.
Pereira E; Spanish Lung Cancer Group, Barcelona, Spain.
Fassunke J; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Fischer RN; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Gardizi M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Heukamp L; Institute of Hematopatholgy Hamburg, Hamburg, Germany, and Lung Cancer Network NOWEL, Oldenburg, Germany.
Insa A; Hospital Clínico Universitario de Valencia, València, Spain.
Kron A; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Menon R; NEO New Oncology GmbH, Cologne, Germany.
Persigehl T; Department of Radiology, University Hospital Cologne, Cologne, Germany.
Reck M; Department for Thoracic Oncology, Airway Research Center North (ARCN), German Center for Lung Research, LungenClinic Grosshansdorf, Großhansdorf, Germany.
Riedel R; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Rothschild SI; University Hospital Basel, Department Internal Medicine, Medical Oncology, Basel, Switzerland.
Scheel AH; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Schmalz P; Clinical Trials Centre Cologne (CTCC) Medical Faculty, University of Cologne, Cologne, Germany.
Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Limburg M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Provencio M; Department of Medical Oncology, Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Spain.
Karachaliou N; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain.
Merkelbach-Bruse S; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Hellmich M; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
Nogova L; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Büttner R; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Rosell R; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Jul; Vol. 14 (7), pp. 1266-1276. Date of Electronic Publication: 2019 Apr 09.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Rearrangement*
Brain Neoplasms/*drug therapy
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Protein-Tyrosine Kinases/*genetics
Proto-Oncogene Proteins/*genetics
Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/genetics ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Response Evaluation Criteria in Solid Tumors ; Survival Rate
Czasopismo naukowe
Tytuł :
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Autorzy :
Scheffler M; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Ihle MA; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Hein R; University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany.
Merkelbach-Bruse S; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Scheel AH; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Siemanowski J; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Brägelmann J; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Kron A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Abedpour N; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Ueckeroth F; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Schüller M; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Koleczko S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Michels S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Fassunke J; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Pasternack H; Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Leibniz Center for Medicine and Biosciences.
Heydt C; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Serke M; Lung Clinic Hemer, Department for Pulmonology and Thoracic Oncology, Hemer, Germany.
Fischer R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Schulte W; GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany.
Gerigk U; GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany.
Nogova L; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Ko YD; Evangelical Clinics of Bonn, Johanniter Hospital, Bonn, Germany.
Abdulla DSY; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Riedel R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Kambartel KO; Bethanien Hospital Moers, Lung Center, Moers, Germany.
Lorenz J; Hospital Lüdenscheid, Clinic for Pneumology, Internistic Intensive Medicine, Infectiology and Sleep Medicine, Lüdenscheid, Germany.
Sauerland I; Hospital Lüdenscheid, Clinic for Pneumology, Internistic Intensive Medicine, Infectiology and Sleep Medicine, Lüdenscheid, Germany.
Randerath W; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Kaminsky B; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Hagmeyer L; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Grohé C; Evangelic Lung Clinic Berlin, Department of Respiratory Diseases, Berlin, Germany.
Eisert A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Frank R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Gogl L; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Schaepers C; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Holzem A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Hellmich M; University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany.
Thomas RK; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Peifer M; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Sos ML; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Büttner R; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Wolf J; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Apr; Vol. 14 (4), pp. 606-616. Date of Electronic Publication: 2018 Dec 31.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation
Czasopismo naukowe
Tytuł :
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer.
Autorzy :
Michels S; University Hospital of Cologne, Cologne, Germany.
Heydt C; University Hospital of Cologne, Cologne, Germany.
van Veggel B; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Deschler-Baier B; University Hospital of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Pardo N; Vall d'Hebron University Hospital, Barcelona, Spain.
Monkhorst K; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rüsseler V; University Hospital of Cologne, Cologne, Germany.
Stratmann J; University Hospital of Frankfurt, Frankfurt, Germany.
Griesinger F; Pius Hospital Oldenburg and Lung Cancer Network NOWEL, Oldenburg, Germany.
Steinhauser S; University of Cologne, Cologne, Germany.
Kostenko A; University Hospital of Cologne, Cologne, Germany.
Diebold J; Cantonal Hospital Lucerne, Lucerne, Switzerland.
Fassunke J; University Hospital of Cologne, Cologne, Germany.
Fischer R; University Hospital of Cologne, Cologne, Germany.
Engel-Riedel W; Lung Clinic Merheim and Hospitals of Cologne, Cologne, Germany.
Gautschi O; Cantonal Hospital Lucerne, Lucerne, Switzerland.
Geissinger E; University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Haneder S; University Hospital of Cologne, Cologne, Germany.
Ihle MA; University Hospital of Cologne, Cologne, Germany.
Kopp HG; Robert Bosch Centrum für Tumorerkrankungen, Stuttgart, Germany.
de Langen AJ; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Martinez-Marti A; Vall d'Hebron University Hospital, Barcelona, Spain.
Nogova L; University Hospital of Cologne, Cologne, Germany.
Persigehl T; University Hospital of Cologne, Cologne, Germany.
Plenker D; University Hospital of Cologne, Cologne, Germany.
Puesken M; University Hospital of Cologne, Cologne, Germany.
Rodermann E; Private practice in Hematology and Oncology, Troisdorf, Germany.
Rosenwald A; University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Scheel AH; University Hospital of Cologne, Cologne, Germany.
Scheffler M; University Hospital of Cologne, Cologne, Germany.
Spengler W; University Hospital of Tübingen. Tübingen, Germany.
Seggewiss-Bernhardt R; Sozialstiftung Bamberg, Bamberg, Germany.
Brägelmann J; University Hospital of Cologne, Cologne, Germany.; University of Cologne, Cologne, Germany.
Sebastian M; University Hospital of Frankfurt, Frankfurt, Germany.
Vrugt B; University Hospital Zurich, Zurich, Switzerland.
Hellmich M; University of Cologne, Cologne, Germany.
Sos ML; University Hospital of Cologne, Cologne, Germany.; University of Cologne, Cologne, Germany.
Heukamp LC; Hematopathology Hamburg and Lung Cancer Network NOWEL, Hamburg, Germany.
Felip E; Vall d'Hebron University Hospital, Barcelona, Spain.
Merkelbach-Bruse S; University Hospital of Cologne, Cologne, Germany.
Smit EF; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Büttner R; University Hospital of Cologne, Cologne, Germany.
Wolf J; University Hospital of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
JCO precision oncology [JCO Precis Oncol] 2019 Mar 27; Vol. 3. Date of Electronic Publication: 2019 Mar 27 (Print Publication: 2019).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[ F]fluoroethyl)-L-tyrosine PET.
Autorzy :
Abdulla DSY; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Brandes V; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Ruge M; Center for Integrated Oncology Köln, Bonn, Germany; Department of Stereotaxy and Functional Neurosurgery, University Hospital of Cologne, Cologne, Germany.
Kunze S; Center for Integrated Oncology Köln, Bonn, Germany; Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany.
Merkelbach-Bruse S; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany; Department of Pathology, University Hospital of Cologne, Cologne, Germany.
Nogova L; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Michels S; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Fischer R; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Riedel R; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Büttner R; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany; Department of Pathology, University Hospital of Cologne, Cologne, Germany.
Persigehl T; Center for Integrated Oncology Köln, Bonn, Germany; Department of Radiology, University Hospital of Cologne, Cologne, Germany.
Grau S; Center for Integrated Oncology Köln, Bonn, Germany; Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany.
Galldiks N; Center for Integrated Oncology Köln, Bonn, Germany; Department of Neurology, University Hospital of Cologne, Cologne, Germany; Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany.
Drzezga A; Center for Integrated Oncology Köln, Bonn, Germany; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
Kobe C; Center for Integrated Oncology Köln, Bonn, Germany; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
Wolf J; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Clinical lung cancer [Clin Lung Cancer] 2019 Mar; Vol. 20 (2), pp. e148-e151. Date of Electronic Publication: 2018 Nov 05.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Brain Neoplasms/*diagnosis
Carcinoma, Non-Small-Cell Lung/*diagnosis
Erlotinib Hydrochloride/*therapeutic use
Lung Neoplasms/*diagnosis
Tyrosine/*analogs & derivatives
Adult ; Brain Neoplasms/drug therapy ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/secondary ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Mutation/genetics ; Positron-Emission Tomography
Czasopismo naukowe
Tytuł :
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Autorzy :
Quaas A; Institute of Pathology, University of Cologne, Cologne, Germany. .
Heydt C; Institute of Pathology, University of Cologne, Cologne, Germany.
Waldschmidt D; Department of Hepato- and Gastroenterology, University of Cologne, Cologne, Germany.
Alakus H; Department of Visceral Surgery, University of Cologne, Cologne, Germany.
Zander T; Department of Oncology and Hematology, University of Cologne, Cologne, Germany.
Goeser T; Department of Hepato- and Gastroenterology, University of Cologne, Cologne, Germany.
Kasper P; Department of Hepato- and Gastroenterology, University of Cologne, Cologne, Germany.
Bruns C; Department of Visceral Surgery, University of Cologne, Cologne, Germany.
Brunn A; Institute of Neuropathology, University of Cologne, Cologne, Germany.
Roth W; Institute of Pathology, University of Mainz, Mainz, Germany.
Hartmann N; Institute of Pathology, University of Mainz, Mainz, Germany.
Bunck A; Department of Radiology, University of Cologne, Cologne, Germany.
Schmidt M; Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
Buettner R; Institute of Pathology, University of Cologne, Cologne, Germany.
Merkelbach-Bruse S; Institute of Pathology, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
BMC gastroenterology [BMC Gastroenterol] 2019 Feb 04; Vol. 19 (1), pp. 21. Date of Electronic Publication: 2019 Feb 04.
Typ publikacji :
Journal Article
MeSH Terms :
Intestine, Small*
Microsatellite Instability*
Precision Medicine*
Adenocarcinoma/*therapy
BRCA2 Protein/*genetics
Intestinal Neoplasms/*therapy
Receptor, ErbB-2/*genetics
Ubiquitin-Protein Ligases/*genetics
Adenocarcinoma/genetics ; Aged ; DNA Repair/genetics ; Humans ; Intestinal Neoplasms/genetics ; Middle Aged ; Mutation
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies